DocGo (DCGO) Q2 Revenue Falls 51%

DocGo reported Q2 2025 GAAP revenue of $80.4 million, surpassing analyst estimates but down 51.2% year-over-year due to the planned wind-down of high-margin government contracts. The company recorded a GAAP net loss of $13.3 million and negative adjusted EBITDA of $(6.1) million, reflecting profitability and margin compression during its business reset. Despite these transitional challenges, management reiterated full-year guidance, highlighted strong operating cash flow of $33.6 million, and reported an increased cash balance to $128.7 million, underscoring progress in cost control and a strategic pivot towards more stable payer/provider and transportation business lines, with profitability targeted by the second half of 2026.

Analysis

DocGo's (NASDAQ:DCGO) second-quarter 2025 results illustrate a company in a deep, planned strategic transition, moving away from high-margin, short-term government contracts. While Q2 revenue of $80.4 million surpassed analyst estimates by 3.6%, the 51.2% year-over-year decline underscores the impact of exiting these legacy programs. This shift directly compressed profitability, flipping adjusted EBITDA to a loss of $(6.1) million from a $17.2 million gain in the prior year and resulting in a GAAP net loss of $13.3 million. Despite these headline declines, the company demonstrated operational resilience by generating $33.6 million in operating cash flow and increasing its cash balance to $128.7 million, bolstered by the collection of legacy receivables. Management's decision to reiterate full-year guidance for revenue ($300M-$330M) and adjusted EBITDA loss ($(20)M-$(30)M) signals confidence in the ongoing pivot. Key growth indicators are emerging in the new core business lines: the transportation segment saw modest revenue growth to $49.6 million and secured a significant new partnership, while the mobile health segment saw patients assigned for care gap services jump from 900,000 to over 1.2 million, indicating strong underlying demand even as top-line revenue adjusts. The company's focus is now clearly on scaling these recurring revenue streams, controlling SG&A expenses through measures expected to save $10 million annually, and reaching overall profitability by the second half of 2026.

Key Decisions for Investors

• Investors should assess DocGo as a turnaround story, focusing on execution in the new core payer/provider and transportation segments rather than the expected year-over-year revenue and profit declines.
• It is critical to monitor margin progression in the core business and the growth rate of key performance indicators, such as the 1.2 million patients assigned for care gap services, as these are the primary drivers for achieving the 2026 profitability target.
• The strong cash position and positive operating cash flow provide a crucial buffer during this transition, but continued timely collection of the remaining ~$54 million in government receivables should be watched closely.
• Consider the reiterated full-year guidance as the baseline expectation, with any new government contracts or faster-than-expected ramp-up from new partnerships representing potential upside to the current plan.